Harlan Krumholz

So trying to get really good evidence based together quickly.

And I think that would surprise most people.

It certainly surprised me.

I mean, this is within three months of it becoming aware and probably within about six weeks.

And we've got 81 trials on the platform and that number will only grow.

And I think that's interesting reassurance that we're starting to get our act together in what we call trial platforms.

People getting some of the regulatory issues out of the way so we can speed up the translation of evidence, particularly from informative trials.

Well, I think we're starting to get our act together.

I think this one is really the 2009 was a sort of wake up call.

And then this is a sort of like it's not just a wake up call.

This is a sort of like call to action.

And so I think out of this again, we'll learn again.

But we have to now be clearer about actually we have to have these novel agencies, platforms ready to go.

And that will require funding up front for when an infection emerges like this.

But I think one of the biggest things that drives our sort of thinking around this is particularly the case fatality rate.

And so one of the things about swine flu is really concerned that this was a pandemic, had high morbidity but mortality, but actually the case fatality rate of swine flu was very low, 0.02%.

So that's incredibly low compared to something like SARS, which was about 9% to 10%.

Now, the question of what we want to know is, what's the case fatality rate of coronavirus?

And this is an incredibly interesting issue.

And it seems like there's some variability depending on the context.